STOCK TITAN

Indivior Pharmaceuticals (INDV) Stock News

INDV NASDAQ

Ticker history: INDV became SUPN (Indivior Pharmaceuticals, Inc.) on .

Indivior Pharmaceuticals, Inc. reports developments in specialty pharmaceuticals for opioid use disorder, with recurring updates centered on SUBLOCADE, its monthly extended-release buprenorphine injection, and evidence supporting medications for opioid use disorder. Company news commonly covers financial results and guidance, commercial performance for SUBLOCADE, scientific and real-world evidence studies, and treatment-use discussions in settings such as correctional facilities.

Indivior updates also include capital-allocation actions, including share repurchase programs and convertible note financing, along with corporate presentations and investor communications tied to the Indivior Action Agenda. The company’s disclosures frame opioid use disorder as a chronic treatable brain disease and emphasize buprenorphine-based prescription treatments.

Rhea-AI Summary

Indivior (INDV) reported third-quarter 2026 net revenue of $356 million, up 13% year over year, alongside higher earnings. SUBLOCADE revenue rose 22% to $267 million. GAAP net income increased to $137 million, or $1.12 per diluted share, from $42 million, or $0.33. Adjusted EBITDA, a non-GAAP earnings measure, rose 76% to $211 million.

Nine-month revenue increased 15% to $1,016 million, while operating cash flow rose to $317 million from $194 million. Quarter-end cash and investments totaled $332 million. Shareholders approved the all-stock merger with Supernus, which Indivior expects to close November 2, 2026. A declared special cash dividend depends on closing. Indivior expects to meet its standalone 2026 guidance, but that guidance will no longer apply if the merger closes as assumed. Current debt was $488 million at September 30, compared with $29 million at year-end 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
-
Rhea-AI Summary

Huron Consulting Group (HURN) will join the S&P SmallCap 600 before trading opens November 3, 2026, replacing Supernus Pharmaceuticals (SUPN).

The effective date moves from November 2 to November 3. Huron will enter the index in the Industrials sector. Indivior Pharmaceuticals (INDV), an existing index constituent, is acquiring Supernus in a transaction expected to close soon, subject to final closing conditions. After the merger, Indivior will assume the name Supernus and trade under SUPN, while remaining in the S&P SmallCap 600.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
-
Rhea-AI Summary

Arbor Realty Trust (ABR) will leave the S&P SmallCap 600 before trading opens on October 28, 2026, as index membership changes. MSG Rangers (MSGR) will join before trading opens on October 27. Madison Square Garden Sports (MSGS) is spinning off MSG Rangers in a transaction expected to be completed on October 27. Madison Square Garden Sports will be renamed MSG Knickerbockers (MSGK) and remain in the index.

Huron Consulting Group (HURN) will replace Supernus Pharmaceuticals (SUPN) before trading opens on November 2, 2026. Indivior Pharmaceuticals (INDV) is acquiring Supernus in a deal expected to be completed soon, pending final closing conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none
Rhea-AI Summary

Indivior Pharmaceuticals (INDV) will report its third quarter 2026 financial results on Thursday, October 29, 2026. Results will be released at 7:00 a.m. U.S. EDT and will be available on the company’s website at www.indivior.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
earnings date
-
Rhea-AI Summary

Indivior Pharmaceuticals (INDV) declared a contingent special cash dividend of $8.13 per share, payable to holders of record of its common stock as of October 30, 2026, and to certain equity award holders via equivalent payments upon vesting.

Payment of the dividend depends on the closing of Indivior’s pending merger with Supernus Pharmaceuticals, which is expected on or about November 2, 2026, following required stockholder approvals and satisfaction or waiver of all merger agreement conditions. If the merger closes on that date, eligible record holders are anticipated to receive the cash dividend on or about November 6, 2026. Supernus stockholders will not receive the special dividend on any Indivior shares issued as merger consideration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.90%
Tags
dividends
-
Rhea-AI Summary

Indivior (Nasdaq: INDV) reported Q2 2026 total net revenue of $343 million, up 14% year-over-year, driven by record quarterly SUBLOCADE net revenue of $253 million, up 21%. U.S. SUBLOCADE revenue rose 22% to $238 million on 18% dispense unit growth and record 32,816 new patient starts.

Q2 2026 GAAP net income reached a record $122 million ($0.98 diluted EPS) and non-GAAP net income was $142 million ($1.15 diluted EPS). Adjusted EBITDA was a record $186 million, up 111% from Q2 2025, as GAAP operating expenses fell 25% to $134 million and non-GAAP operating expenses declined 33% to $112 million.

For full-year 2026, Indivior raised guidance, now expecting net revenue of $1,295–$1,365 million, total SUBLOCADE net revenue of $1,010–$1,050 million, and adjusted EBITDA of $700–$740 million, while maintaining non-GAAP operating expense guidance. The company repurchased approximately 4.7 million shares for $175 million in Q2 (8.6 million shares, $300 million year-to-date) and ended the quarter with $249 million in cash and investments. Indivior and Supernus also announced a definitive agreement for an all-stock merger of equals, expected to close in the fourth quarter of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.60%
Tags
Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) and Indivior Pharmaceuticals (Nasdaq: INDV) agreed to a tax-free, all-stock merger of equals to form a diversified CNS biopharmaceutical company with pro forma net revenue of approximately $2.2 billion and pro forma adjusted EBITDA of $888 million, including $125 million in expected annual cost synergies.

Supernus stockholders will receive 1.5401 Indivior shares per share and Indivior stockholders will receive a one-time special cash dividend of $1.0 billion, funded by a committed $650 million term loan from Citibank N.A. and existing cash. Indivior holders will own about 56.5% of the combined company and Supernus holders about 43.5%. The merged entity will be named Supernus, Inc., listed on Nasdaq as SUPN, headquartered in Rockville, Maryland, led by Supernus CEO Jack Khattar as President and CEO and Indivior director Tony Kingsley as Board Chair. Closing is targeted for Q4 2026, subject to shareholder and regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.60%
Tags
-
Rhea-AI Summary

Indivior (Nasdaq: INDV) will release its second quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S. EDT. At 8:00 a.m. U.S. EDT, CEO Joe Ciaffoni and the leadership team will host a live webcast presentation, accessible via the Investors section of www.indivior.com, with telephonic access by advance online registration and a replay available on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
earnings date
-
Rhea-AI Summary

Indivior (Nasdaq: INDV) reported two real‑world evidence studies on monthly injectable buprenorphine (SUBLOCADE) in opioid use disorder.

Adherent patients were 3.5–8.1x less likely to return to opioid use, had 62% lower bacteremia incidence, and showed reduced inpatient, emergency, and outpatient healthcare utilization versus other MOUD or daily oral buprenorphine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
none
Rhea-AI Summary

Indivior (Nasdaq: INDV) will participate in two June 2026 investor conferences. Management will attend the Jefferies Global Healthcare Conference in New York on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, hosting 1x1 and group investor meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences

FAQ

What is the current stock price of Indivior Pharmaceuticals (INDV)?

Indivior Pharmaceuticals (INDV) last closed at $36.28. The company now trades as SUPN.